Blood cell markers in primary and secondary antiphospholipid syndrome
Compares blood cell markers in adults with primary versus secondary antiphospholipid syndrome.
Key facts
- Who runs it
- New Valley University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 27 Nov 2025
- Expected to end
- 30 Jun 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- • Complete blood count , MPV
- Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:
- Antiphospholipid antibody profile
- Record updated
- 31 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with antiphospholipid syndrome (APS), either primary or secondary. It compares simple blood count markers between these two groups.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- APS diagnosed by the updated Sydney classification criteria. People must have had blood clots and/or pregnancy problems. Both primary APS and secondary APS can join.
- Earlier treatment
- People cannot join after a recent blood transfusion. They also cannot join if they take medicines that change platelets, other than APS treatments.
- Biomarker or test result
- Antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant) found persistently, for ≥12 weeks.
Main reasons for not taking part
- Current infection or inflammation not caused by APS
- Blood cancers or other blood disorders
- Recent blood transfusion
- Platelet-altering medicines other than APS treatments
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adults (age ≥18 years)
- Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and/or pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant)
Who cannot take part
- Current infection or inflammatory condition unrelated to APS
- Hematological malignancies or other blood disorders
- Recent blood transfusion or platelet-altering medications other than APS treatments
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease course. Clinical presentation in antiphospholipid syndrome includes venous and arterial thrombosis, pregnancy complications, and a broad range of microvascular and non-thrombotic manifestations
The 2 groups in the trial
- 1
Primary APS
Treatment: • Complete blood count , MPV, Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:, and Antiphospholipid antibody profile
- 2
secondary APS
Treatment: • Complete blood count , MPV, Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:, and Antiphospholipid antibody profile
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparative Analysis of Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome
- Plain-language title
- Blood cell markers in primary and secondary antiphospholipid syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 31 July 2026